2004
DOI: 10.1016/j.neuropharm.2003.11.013
|View full text |Cite
|
Sign up to set email alerts
|

The selective mGlu2/3 receptor antagonist LY341495 exacerbates behavioral signs of morphine withdrawal and morphine-withdrawal-induced activation of locus coeruleus neurons

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

3
11
0

Year Published

2005
2005
2012
2012

Publication Types

Select...
7
1
1

Relationship

0
9

Authors

Journals

citations
Cited by 28 publications
(14 citation statements)
references
References 41 publications
3
11
0
Order By: Relevance
“…With regard to the latter two signs reduced by the GCP II inhibitor, one may hypothesize that the diminution of glutamatergic tone associated with 2-MPPA administration attenuates some indices of naloxone-precipitated opioid withdrawal, as have been reported for other inhibitors of glutamatergic neurotransmission (e.g., Jhamandas et al 1996;Fundytus and Coderre 1997;Klodzinska et al 1999;Palucha et al 2004). The fact that the intensity of ptosis was increased by LY341495 is also consistent with the study of Rasmussen et al (2004). The authors reported that the mGluR2/3 antagonist LY341495 augmented various signs of opioid withdrawal in rats.…”
Section: Discussionsupporting
confidence: 83%
“…With regard to the latter two signs reduced by the GCP II inhibitor, one may hypothesize that the diminution of glutamatergic tone associated with 2-MPPA administration attenuates some indices of naloxone-precipitated opioid withdrawal, as have been reported for other inhibitors of glutamatergic neurotransmission (e.g., Jhamandas et al 1996;Fundytus and Coderre 1997;Klodzinska et al 1999;Palucha et al 2004). The fact that the intensity of ptosis was increased by LY341495 is also consistent with the study of Rasmussen et al (2004). The authors reported that the mGluR2/3 antagonist LY341495 augmented various signs of opioid withdrawal in rats.…”
Section: Discussionsupporting
confidence: 83%
“…Naloxone administration following chronic injections of morphine induced behavioral signs of withdrawal in rats, which is in agreement with other studies (Rasmussen et al, 2004;Dizgah et al, 2005).…”
Section: Discussionsupporting
confidence: 93%
“…First, MK-801 ([+]-5-methyl-10,11,dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate; Sigma-Aldrich; 0.2 mg/kg IP) was used to block NMDA receptors known to exist in the olfactory system (Wilson et al 1996). Second, LY341495 (Tocris Bioscience; 2.5 mg/kg IP), a metabotropic glutamate receptor II/III antagonist capable of crossing the blood-brain barrier (O'Neill et al 2003;Rasmussen et al 2004), was used to block the activity of mGluR II/III metabotropic glutamate receptors in the olfactory system (Best and Wilson 2004).…”
Section: Pharmacologymentioning
confidence: 99%